ReachMD Cardiology

Episodes 1-16 of 99

- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
  Peer
- Charles P. Vega, MD
  Peer
5
CME/CE Broadcast Replay
CME/CE Broadcast Replay
Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction
Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction
1.00 credits
Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction
1.00 credits
- Marco Metra, MD
  Peer
- Adrian F. Hernandez, MD, MHS
  Peer
6
Global Heart Failure Academy
From Paper to Patient: Applying Guideline Updates to Practice
From Paper to Patient: Applying Guideline Updates to Practice
From Paper to Patient: Applying Guideline Updates to Practice
- Mikhail Kosiborod, MD
  Peer
- Michael Böhm, MD, FESC
  Peer
7
Global Heart Failure Academy
The 4 Pillars of Treatment in HFrEF: Does Risk of Hyperkalemia Threaten to Topple Them Over?
The 4 Pillars of Treatment in HFrEF: Does Risk of Hyperkalemia Threaten to Topple Them Over?
The 4 Pillars of Treatment in HFrEF: Does Risk of Hyperkalemia Threaten to Topp…
- Christie M. Ballantyne, MD
  Peer
- Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP
  Peer
- Joseph Saseen, PharmD, BCPS, BCACP, CLS
  Peer
- Karol Watson, MD, PhD
  Peer
15
CME/CE Broadcast Replay
CME/CE Broadcast Replay
Adopting the New Therapeutic “Lineup” to Manage ASCVD - Central
Adopting the New Therapeutic “Lineup” to Manage ASCVD - Central
3.50 credits
Adopting the New Therapeutic “Lineup” to Manage ASCVD - Central
3.50 credits
- Ahmad Masri, MD, MS
  Peer
- Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
  Peer
2
CME/CE
Emerging Therapies in Hypertrophic Cardiomyopathy: The Potential Role of Cardiac Myosin Inhibition
Emerging Therapies in Hypertrophic Cardiomyopathy: The Potential Role of Cardiac Myosin Inhibition
0.25 credits
Emerging Therapies in Hypertrophic Cardiomyopathy: The Potential Role of Cardia…
0.25 credits
- Mikhail Kosiborod, MD
  Peer
- Austin G. Stack, MBBCh, MD, MSc, FASN, FRCPI
  Peer
12
CME/CE
New Perspectives in Managing HF and HK – The Cardiorenal Angle
New Perspectives in Managing HF and HK – The Cardiorenal Angle
0.25 credits
New Perspectives in Managing HF and HK – The Cardiorenal Angle
0.25 credits
- Ahmad Masri, MD, MS
  Peer
- Steve R. Ommen, MD
  Peer
6
CME/CE
Hypertrophic Cardiomyopathy: The 3 Things You Need to Know
Hypertrophic Cardiomyopathy: The 3 Things You Need to Know
0.25 credits
Hypertrophic Cardiomyopathy: The 3 Things You Need to Know
0.25 credits
- Michael Miller, MD, FACC, FAHA, FNLA
  Peer
- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
  Peer
- Aruna Pradhan, MD, MPH
  Peer
- James A. Underberg, MD
  Peer
9
CME/CE Broadcast Replay
CME/CE Broadcast Replay
Adopting the New Therapeutic “Lineup” to Manage ASCVD - East
Adopting the New Therapeutic “Lineup” to Manage ASCVD - East
3.50 credits
Adopting the New Therapeutic “Lineup” to Manage ASCVD - East
3.50 credits
- Josep Comin-Colet, MD, PhD
  Peer
10
CME/CE
Beyond Anemia: Addressing Iron Deficiency in Patients with Heart Failure
Beyond Anemia: Addressing Iron Deficiency in Patients with Heart Failure
0.25 credits
Beyond Anemia: Addressing Iron Deficiency in Patients with Heart Failure
0.25 credits
- Mark J. Alberts, MD
  Peer
- Matthew Jay Budoff, MD
  Peer
- Lawrence A. Leiter, MD
  Peer
6
CME/CE
Omega-3 Icosapent Ethyl and Stroke Reduction in Atherosclerotic Vascular Disease
Omega-3 Icosapent Ethyl and Stroke Reduction in Atherosclerotic Vascular Disease
0.75 credits
Omega-3 Icosapent Ethyl and Stroke Reduction in Atherosclerotic Vascular Disease
0.75 credits
- Javed Butler, MD, MBA, MPH
  Peer
- Stefan D. Anker, MD, PhD
  Peer
17
CME/CE
Approaching Optimal RAASi Therapy with Use of Potassium Binders: DIAMOND Topline Results
Approaching Optimal RAASi Therapy with Use of Potassium Binders: DIAMOND Topline Results
0.25 credits
Approaching Optimal RAASi Therapy with Use of Potassium Binders: DIAMOND Toplin…
0.25 credits
- Javed Butler, MD, MBA, MPH
  Peer
- Shelley Zieroth, MD
  Peer
11
CME/CE
High-Risk HFrEF: Who Will Benefit Most from Novel Therapies?
High-Risk HFrEF: Who Will Benefit Most from Novel Therapies?
0.25 credits
High-Risk HFrEF: Who Will Benefit Most from Novel Therapies?
0.25 credits
- Peter Rossing, DMSc, MD
  Peer
- Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
  Peer
- Matthew R. Weir, MD
  Peer
10
CME/CE
New Insights into the Management of CKD in T2D: The Role of MRA Therapies
New Insights into the Management of CKD in T2D: The Role of MRA Therapies
0.25 credits
New Insights into the Management of CKD in T2D: The Role of MRA Therapies
0.25 credits
- Murray Epstein, MD
  Peer
- Gates B. Colbert, MD, FASN
  Peer
1
CME/CE
Considerations When Using a Potassium Binder in Patients with CKD
Considerations When Using a Potassium Binder in Patients with CKD
0.25 credits
Considerations When Using a Potassium Binder in Patients with CKD
0.25 credits
- Peter van der Meer, MD, PhD
  Peer
- Pieter Martens, MD, PhD
  Peer
8
CME/CE
New Perspectives on the Management of HFrEF: Iron Deficiency and Cardiac Remodeling
New Perspectives on the Management of HFrEF: Iron Deficiency and Cardiac Remodeling
0.25 credits
New Perspectives on the Management of HFrEF: Iron Deficiency and Cardiac Remode…
0.25 credits
- George L. Bakris, MD
  Peer
- Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
  Peer
3
CME/CE
Optimizing RAASi Therapy: The Role of Personalized Medicine
Optimizing RAASi Therapy: The Role of Personalized Medicine
0.25 credits
Optimizing RAASi Therapy: The Role of Personalized Medicine
0.25 credits